Literature DB >> 31073762

Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasis.

Demond Williams1, Barbara Fingleton2.   

Abstract

Metabolic alterations are established as a hallmark of cancer. Such hallmark changes in cancer metabolism are characterized by reprogramming of energy-producing pathways and increases in the generation of biosynthetic intermediates to meet the needs of rapidly proliferating tumor cells. Various metabolic phenotypes such as aerobic glycolysis, increased glutamine consumption, and lipolysis have also been associated with the process of metastasis. However, in addition to the energy and biosynthetic alterations, a number of secondary functions of enzymes and metabolites are emerging that specifically contribute to metastasis. Here, we describe atypical intracellular roles of metabolic enzymes, extracellular functions of metabolic enzymes, roles of metabolites as signaling molecules, and epigenetic regulation mediated by altered metabolism, all of which can affect metastatic progression. We highlight how some of these mechanisms are already being exploited for therapeutic purposes, and discuss how others show similar potential.

Entities:  

Keywords:  ATP citrate lyase; Epigenetic; Glutaminase; Mutant isocitrate dehydrogenase; Phosphohexose isomerase

Mesh:

Substances:

Year:  2019        PMID: 31073762      PMCID: PMC6538276          DOI: 10.1007/s10585-019-09967-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  120 in total

1.  Germline SDHD mutation in familial phaeochromocytoma.

Authors:  D Astuti; F Douglas; T W Lennard; I A Aligianis; E R Woodward; D G Evans; C Eng; F Latif; E R Maher
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins.

Authors:  T Torimura; T Ueno; M Kin; R Harada; T Nakamura; T Kawaguchi; M Harada; R Kumashiro; H Watanabe; R Avraham; M Sata
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

3.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.

Authors:  Ian P M Tomlinson; N Afrina Alam; Andrew J Rowan; Ella Barclay; Emma E M Jaeger; David Kelsell; Irene Leigh; Patricia Gorman; Hanan Lamlum; Shamima Rahman; Rebecca R Roylance; Simon Olpin; Stephen Bevan; Karen Barker; Nicholas Hearle; Richard S Houlston; Maija Kiuru; Rainer Lehtonen; Auli Karhu; Susa Vilkki; Päivi Laiho; Carita Eklund; Outi Vierimaa; Kristiina Aittomäki; Marja Hietala; Pertti Sistonen; Anders Paetau; Reijo Salovaara; Riitta Herva; Virpi Launonen; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2002-02-25       Impact factor: 38.330

4.  Identification of a soluble form phospholipase A2 receptor as a circulating endogenous inhibitor for secretory phospholipase A2.

Authors:  Ken-ichi Higashino Ki; Yasunori Yokota; Takashi Ono; Shigeki Kamitani; Hitoshi Arita; Kohji Hanasaki
Journal:  J Biol Chem       Date:  2002-02-05       Impact factor: 5.157

5.  Detachment of glycolytic enzymes from cytoskeleton of Lewis lung carcinoma and colon adenocarcinoma cells induced by clotrimazole and its correlation to cell viability and morphology.

Authors:  Julia Penso; Rivka Beitner
Journal:  Mol Genet Metab       Date:  2002-07       Impact factor: 4.797

6.  Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells.

Authors:  Tatsuyoshi Funasaka; Arayo Haga; Avraham Raz; Hisamitsu Nagase
Journal:  Int J Cancer       Date:  2002-09-20       Impact factor: 7.396

7.  Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid.

Authors:  Tatsuyoshi Funasaka; Arayo Haga; Avraham Raz; Hisamitsu Nagase
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

8.  Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-beta.

Authors:  Takashi Yanagawa; Hideomi Watanabe; Toshiyuki Takeuchi; Shuhei Fujimoto; Hideyuki Kurihara; Kenji Takagishi
Journal:  Lab Invest       Date:  2004-04       Impact factor: 5.662

9.  Activation of small GTPase Rho is required for autocrine motility factor signaling.

Authors:  Soichi Tsutsumi; Suresh K Gupta; Victor Hogan; John G Collard; Avraham Raz
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells.

Authors:  H Niizeki; M Kobayashi; I Horiuchi; N Akakura; J Chen; J Wang; J-i Hamada; P Seth; H Katoh; H Watanabe; A Raz; M Hosokawa
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

View more
  5 in total

1.  H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth.

Authors:  Chunwan Lu; Dafeng Yang; John D Klement; Yolonda L Colson; Nicholas H Oberlies; Cedric J Pearce; Aaron H Colby; Mark W Grinstaff; Zhuoqi Liu; Huidong Shi; Han-Fei Ding; Kebin Liu
Journal:  Oncogene       Date:  2022-03-30       Impact factor: 8.756

2.  Assessment of biochemical recurrence of prostate cancer (Review).

Authors:  Xiaozeng Lin; Anil Kapoor; Yan Gu; Mathilda Jing Chow; Hui Xu; Pierre Major; Damu Tang
Journal:  Int J Oncol       Date:  2019-10-04       Impact factor: 5.650

Review 3.  The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression.

Authors:  Filippo Torrisi; Cristiana Alberghina; Simona D'Aprile; Anna M Pavone; Lucia Longhitano; Sebastiano Giallongo; Daniele Tibullo; Michelino Di Rosa; Agata Zappalà; Francesco P Cammarata; Giorgio Russo; Massimo Ippolito; Giacomo Cuttone; Giovanni Li Volti; Nunzio Vicario; Rosalba Parenti
Journal:  Biomedicines       Date:  2022-03-30

Review 4.  Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications.

Authors:  Tiziana Tataranni; Claudia Piccoli
Journal:  Oxid Med Cell Longev       Date:  2019-11-14       Impact factor: 6.543

5.  Nuclear control of lung cancer cells migration, invasion and bioenergetics by eukaryotic translation initiation factor 3F.

Authors:  Pauline Esteves; Laetitia Dard; Aurélia Brillac; Christophe Hubert; Saharnaz Sarlak; Benoît Rousseau; Elodie Dumon; Julien Izotte; Marc Bonneu; Didier Lacombe; Jean-William Dupuy; Nivea Amoedo; Rodrigue Rossignol
Journal:  Oncogene       Date:  2019-09-16       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.